SCHEMBL14966540

SCHEMBL14966540

CC(C)OC(C)c1ccc(C(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.55
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48
RXRA P19793 4/20 0.46
RXRB P28702 4/20 0.46
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SRD5A2 P31213 3/20 0.43
MAPK1 P28482 1/20 0.43
ANPEP P15144 1/20 0.43
NR1H4 Q96RI1 1/20 0.42
RXRG P48443 1/20 0.42
MAPT P10636 1/20 0.42
CA12 O43570 1/20 0.41
CA3 P07451 1/20 0.41
TYR P14679 1/20 0.41
DRD1 P21728 1/20 0.41
CA4 P22748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17789907 0.85 KMT2A (0.47) KMT2ATP53TSHRRXRARXRB
SCHEMBL6467238 0.82 CA1 (0.52) KMT2ATP53TSHRRXRARXRB
SCHEMBL14967205 0.81 CA1 (0.52) KMT2ATSHRCA1CA2ALDH1A1
SCHEMBL3075285 0.80 KMT2A (0.50) KMT2ATP53TSHRRXRARXRB
SCHEMBL3075291 0.80 KMT2A (0.50) KMT2ATP53TSHRRXRARXRB
SCHEMBL12559730 0.80 ESR1 (0.33)
SCHEMBL9329056 0.78 KMT2A (0.48) KMT2ATP53TSHRRXRARXRB
SCHEMBL10519895 0.77 AKR1C2 (0.57) KMT2ATP53TSHRRXRARXRB
SCHEMBL1842790 0.77 RXRA (0.47) KMT2ATP53TSHRRXRARXRB
SCHEMBL31541675 0.77 KMT2A (0.47) KMT2ATP53TSHRRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2966099-B1 PARTICLE SIZE DISTRIBUTION CONTROL THROUGH INTERNAL DONOR IN ZIEGLER-NATTA CATALYST INDIAN OIL CORP LTD (IN) 2020-03-11 EP claimed
EP-3018150-B1 PROCESS FOR THE PREPARATION OF SPHERICAL CATALYST PARTICLES INDIAN OIL CORP LTD (IN) 2020-03-11 EP claimed
EP-2958950-B1 AN IMPROVED MAGNESIUM DICHLORIDE SUPPORTED TITANIUM CATALYST COMPOSITION FOR POLYOLEFIN POLYMERIZATION RELIANCE INDUSTRIES LTD (IN) 2019-09-11 EP claimed
EP-3162819-B1 IMPROVED ZIEGLER-NATTA CATALYST SYNTHESIS AND PROCESS THEREOF INDIAN OIL CORP LTD (IN) 2018-09-05 EP claimed
EP-2897985-B1 CATALYST FOR POLYMERIZATION OF OLEFINS AND PROCESS THEREOF INDIAN OIL CORP LTD (IN) 2017-03-08 EP claimed
US-9409865-B2 Modulators of methyl modifying enzymes, compositions and uses thereof Constellation_Pharmaceuticals, Inc. (US) 2016-08-09 US disclosed
US-9409865-B2 Modulators of methyl modifying enzymes, compositions and uses thereof Constellation_Pharmaceuticals, Inc. (US) 2016-08-09 US disclosed
US-9409865-B2 Modulators of methyl modifying enzymes, compositions and uses thereof Constellation_Pharmaceuticals, Inc. (US) 2016-08-09 US disclosed
US-20150315148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2015-11-05 US disclosed
US-20150315148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2015-11-05 US disclosed
US-20150315148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2015-11-05 US disclosed
US-9051269-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-06-09 US disclosed
US-9051269-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-06-09 US disclosed
US-9051269-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-06-09 US disclosed
US-20140315949-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2014-10-23 US disclosed
US-20140315949-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2014-10-23 US disclosed
US-20140315949-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2014-10-23 US disclosed
EP-2780013-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2014-09-24 EP disclosed
WO-2013075084-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2013-05-23 WO disclosed
WO-2013075084-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TET1, TET3, EHMT2 KMT2A 84/4885TP53 2638/4885TSHR 4426/4885
US-20140315949-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TET1, TET3, EHMT2 KMT2A 84/4885TP53 2638/4885TSHR 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.